Cargando…

Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases

Here, we retrospectively review imaging of 68 consecutive unselected patients with BRAF V600‐mutant metastatic melanoma for organ‐specific response and progression on vemurafenib. Complete or partial responses were less often seen in the central nervous system (CNS) (36%) and bone (16%) compared to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seifert, Heike, Hirata, Eishu, Gore, Martin, Khabra, Komel, Messiou, Christina, Larkin, James, Sahai, Erik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737278/ https://www.ncbi.nlm.nih.gov/pubmed/26414886 http://dx.doi.org/10.1111/pcmr.12424

Ejemplares similares

Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling
por: Hirata, Eishu, et al.
Publicado: (2015)

Pazopanib-Induced Alopecia, an Underestimated Toxicity?
por: Biondo, Andrea, et al.
Publicado: (2015)

Observation as a treatment strategy for advanced renal cell carcinoma—a call for prospective validation
por: Fisher, Rosalie, et al.
Publicado: (2012)

Multiple metastases in central nervous system and subdural hematoma in the course of melanoma
por: Woźniak-Dąbrowska, Kamila, et al.
Publicado: (2022)

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities
por: Karz, Alcida, et al.
Publicado: (2022)

Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer
por: Nicoś, Marcin, et al.
Publicado: (2015)

BRAF Alteration in Central and Peripheral Nervous System Tumors
por: Srinivasa, Komal, et al.
Publicado: (2020)

Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors
por: Thanopoulou, Eirini, et al.
Publicado: (2014)

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
por: Fisher, Rosalie, et al.
Publicado: (2012)

BRAF and MEK Targeted Therapies in Pediatric Central Nervous System Tumors
por: Talloa, Dario, et al.
Publicado: (2022)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
por: Reinhard, Raphael, et al.
Publicado: (2018)

Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases
por: PELLEGRINI, Cristina, et al.
Publicado: (2020)

The Influence of Neuron-Extrinsic Factors and Aging on Injury Progression and Axonal Repair in the Central Nervous System
por: Sutherland, Theresa C., et al.
Publicado: (2020)

Exacerbation of Multiple Sclerosis by BRAF/MEK Treatment for Malignant Melanoma: The Central Vein Sign to Distinguish Demyelinating Lesions From Metastases
por: Hemond, Christopher C., et al.
Publicado: (2021)

Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma
por: Tawbi, Hussein, et al.
Publicado: (2022)

Uterine leiomyosarcoma with central nervous system metastases
por: Abrahão, Carina Meira, et al.
Publicado: (2015)

Cytokine Landscape in Central Nervous System Metastases
por: Marin, Julie, et al.
Publicado: (2022)

BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy
por: Chowdhary, Mudit, et al.
Publicado: (2016)

THER-10. IMPACT OF BRAF MUTATIONAL STATUS ON THE EFFICACY OF IMMUNOTHERAPY FOR MELANOMA BRAIN METASTASES
por: Lauko, Adam, et al.
Publicado: (2019)

Hormonal treatments in metastatic endometrial stromal sarcomas: the 10-year experience of the sarcoma unit of Royal Marsden Hospital
por: Thanopoulou, Eirini, et al.
Publicado: (2015)

Leptomeningeal metastases from a primary central nervous system melanoma: a case report and literature review
por: Pan, Zhenyu, et al.
Publicado: (2014)

Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER‐Medicare analysis
por: Sadetsky, Natalia, et al.
Publicado: (2020)

Treatment patterns and clinical outcomes for patients with melanoma and central nervous system metastases: A real‐world study
por: Tawbi, Hussein, et al.
Publicado: (2021)

Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
por: Jain, Tania, et al.
Publicado: (2015)

Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma
por: Satzger, Imke, et al.
Publicado: (2015)

THER-13. IMMUNOTHERAPY VERSUS STANDARD OF CARE IN MELANOMA BRAIN METASTASES WITH KNOWN BRAF STATUS
por: Barnett, Addison, et al.
Publicado: (2019)

Frequency of BRAF V600E mutations in 969 central nervous system neoplasms
por: Behling, Felix, et al.
Publicado: (2016)

The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy
por: Hannan, Enda J., et al.
Publicado: (2017)

Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program
por: Kollàr, Attila, et al.
Publicado: (2014)

The Brain Microenvironment Induces DNMT1 Suppression and Indolence of Metastatic Cancer Cells
por: Hirata, Eishu, et al.
Publicado: (2020)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas
por: Hirata, Amanda S., et al.
Publicado: (2021)

Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma
por: Martin-Liberal, Juan, et al.
Publicado: (2013)

Targeting BRAF for patients with melanoma
por: Arkenau, H-T, et al.
Publicado: (2011)

BRAF Mutation Is Associated with Improved Local Control of Melanoma Brain Metastases Treated with Gamma Knife Radiosurgery
por: Gallaher, Ian S., et al.
Publicado: (2016)

ERK Activity Imaging During Migration of Living Cells In Vitro and In Vivo
por: Hirata, Eishu, et al.
Publicado: (2019)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Transformation of a Silent Adrencorticotrophic Pituitary Tumor Into Central Nervous System Melanoma
por: Miller, Brandon A., et al.
Publicado: (2013)

A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma
por: Larkin, J M G, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_pu3sah2ahvap9c9096qqh9q29a